Polymyxin Resistance Testing Market- Growth, Share, Opportunities & Competitive Analysis, 2024 – 2032
Description
Market Overview:
The Polymyxin Resistance Testing Market is forecasted to expand from USD 137 million in 2024 to approximately USD 230.16 million by 2032, reflecting a compound annual growth rate (CAGR) of 6.7% over the 2024–2032 period.
Market growth is being propelled by several critical factors, notably the escalating threat of antimicrobial resistance (AMR) and the increasing necessity for accurate diagnostic tools to detect polymyxin-resistant infections. As polymyxins represent last-line antibiotics for treating multidrug-resistant Gram-negative bacterial infections, the emergence of resistant strains has significantly heightened demand for effective resistance testing solutions. The healthcare industry's broader shift toward precision medicine and individualized treatment regimens has further supported the integration of advanced diagnostic technologies. Additionally, supportive government policies and initiatives aimed at mitigating AMR are expected to drive adoption and market expansion.
Market Drivers:
Growing Emphasis on Combating Antimicrobial Resistance (AMR):
Antimicrobial resistance continues to pose a serious global health challenge, prompting governments, healthcare providers, and research bodies to intensify efforts against resistant infections. With many conventional antibiotics losing efficacy against evolving bacterial strains, the role of resistance testing has become increasingly crucial. Polymyxin resistance testing, in particular, enables clinicians to detect resistant pathogens promptly and tailor treatment approaches, thereby minimizing the misuse of antibiotics and helping to address the broader AMR crisis. According to the Centers for Disease Control and Prevention (CDC), antimicrobial-resistant infections result in over 2.8 million illnesses and approximately 35,000 deaths annually in the United States alone.
Market Challenges:
High Cost of Advanced Diagnostic Solutions:
A major barrier to widespread adoption within the Polymyxin Resistance Testing Market is the significant cost associated with modern diagnostic technologies. Techniques such as next-generation sequencing (NGS), polymerase chain reaction (PCR), and MALDI-TOF require considerable investment in laboratory infrastructure, equipment, and highly trained personnel. These financial demands can hinder implementation, particularly in lower-income countries and resource-limited healthcare environments. Therefore, there is an ongoing need for cost-effective, scalable diagnostic options that ensure broader access without compromising accuracy or quality.
Market Segmentation:
By Product:
Diagnostic Kits
Reagent Kits
Testing Panels
Instruments
Automated Systems
Antimicrobial Susceptibility Testing (AST) Systems
By Testing Methods:
Molecular Methods
PCR (Polymerase Chain Reaction)
Next-Generation Sequencing (NGS)
Culture-Based Methods
Disk Diffusion
Broth Microdilution
Others
MALDI-TOF (Matrix-Assisted Laser Desorption/Ionization Time-of-Flight)
By End User:
Hospitals
Diagnostic Laboratories
Research Institutions
Others
Academic Institutes
Public Health Organizations
By Region:
North America:
U.S.
Canada
Mexico
Europe:
Germany
France
United Kingdom
Italy
Spain
Rest of Europe
Asia Pacific:
China
Japan
India
South Korea
Southeast Asia
Rest of Asia Pacific
Latin America:
Brazil
Argentina
Rest of Latin America
Middle East & Africa:
GCC Countries
South Africa
Rest of the Middle East and Africa
Key Market Participants:
Thermo Fisher Scientific
Mast Group
Liofilchem
Rosco Diagnostica A/S
bioMérieux SA
Meridian
Beckman Coulter
Becton Dickinson & Company
Accelerate Diagnostics, Inc.
Bruker
EUCAST
Generon S.p.A.
The Polymyxin Resistance Testing Market is forecasted to expand from USD 137 million in 2024 to approximately USD 230.16 million by 2032, reflecting a compound annual growth rate (CAGR) of 6.7% over the 2024–2032 period.
Market growth is being propelled by several critical factors, notably the escalating threat of antimicrobial resistance (AMR) and the increasing necessity for accurate diagnostic tools to detect polymyxin-resistant infections. As polymyxins represent last-line antibiotics for treating multidrug-resistant Gram-negative bacterial infections, the emergence of resistant strains has significantly heightened demand for effective resistance testing solutions. The healthcare industry's broader shift toward precision medicine and individualized treatment regimens has further supported the integration of advanced diagnostic technologies. Additionally, supportive government policies and initiatives aimed at mitigating AMR are expected to drive adoption and market expansion.
Market Drivers:
Growing Emphasis on Combating Antimicrobial Resistance (AMR):
Antimicrobial resistance continues to pose a serious global health challenge, prompting governments, healthcare providers, and research bodies to intensify efforts against resistant infections. With many conventional antibiotics losing efficacy against evolving bacterial strains, the role of resistance testing has become increasingly crucial. Polymyxin resistance testing, in particular, enables clinicians to detect resistant pathogens promptly and tailor treatment approaches, thereby minimizing the misuse of antibiotics and helping to address the broader AMR crisis. According to the Centers for Disease Control and Prevention (CDC), antimicrobial-resistant infections result in over 2.8 million illnesses and approximately 35,000 deaths annually in the United States alone.
Market Challenges:
High Cost of Advanced Diagnostic Solutions:
A major barrier to widespread adoption within the Polymyxin Resistance Testing Market is the significant cost associated with modern diagnostic technologies. Techniques such as next-generation sequencing (NGS), polymerase chain reaction (PCR), and MALDI-TOF require considerable investment in laboratory infrastructure, equipment, and highly trained personnel. These financial demands can hinder implementation, particularly in lower-income countries and resource-limited healthcare environments. Therefore, there is an ongoing need for cost-effective, scalable diagnostic options that ensure broader access without compromising accuracy or quality.
Market Segmentation:
By Product:
Diagnostic Kits
Reagent Kits
Testing Panels
Instruments
Automated Systems
Antimicrobial Susceptibility Testing (AST) Systems
By Testing Methods:
Molecular Methods
PCR (Polymerase Chain Reaction)
Next-Generation Sequencing (NGS)
Culture-Based Methods
Disk Diffusion
Broth Microdilution
Others
MALDI-TOF (Matrix-Assisted Laser Desorption/Ionization Time-of-Flight)
By End User:
Hospitals
Diagnostic Laboratories
Research Institutions
Others
Academic Institutes
Public Health Organizations
By Region:
North America:
U.S.
Canada
Mexico
Europe:
Germany
France
United Kingdom
Italy
Spain
Rest of Europe
Asia Pacific:
China
Japan
India
South Korea
Southeast Asia
Rest of Asia Pacific
Latin America:
Brazil
Argentina
Rest of Latin America
Middle East & Africa:
GCC Countries
South Africa
Rest of the Middle East and Africa
Key Market Participants:
Thermo Fisher Scientific
Mast Group
Liofilchem
Rosco Diagnostica A/S
bioMérieux SA
Meridian
Beckman Coulter
Becton Dickinson & Company
Accelerate Diagnostics, Inc.
Bruker
EUCAST
Generon S.p.A.
Table of Contents
192 Pages
- CHAPTER NO. 1 : INTRODUCTION
- 1.1.1. Report Description
- Purpose of the Report
- USP & Key Offerings
- 1.1.2. Key Benefits for Stakeholders
- 1.1.3. Target Audience
- 1.1.4. Report Scope
- CHAPTER NO. 2 : EXECUTIVE SUMMARY
- 2.1. Polymyxin Resistance Testing Market Snapshot
- 2.1.1. Polymyxin Resistance Testing Market, 2018 - 2032 (USD Million)
- CHAPTER NO. 3 : Polymyxin Resistance Testing Market – INDUSTRY ANALYSIS
- 3.1. Introduction
- 3.2. Market Drivers
- 3.3. Market Restraints
- 3.4. Market Opportunities
- 3.5. Porter’s Five Forces Analysis
- CHAPTER NO. 4 : ANALYSIS COMPETITIVE LANDSCAPE
- 4.1. Company Market Share Analysis – 2023
- 4.2. Polymyxin Resistance Testing Market Company Revenue Market Share, 2023
- 4.3. Company Assessment Metrics, 2023
- 4.4. Start-ups / SMEs Assessment Metrics, 2023
- 4.5. Strategic Developments
- 4.6. Key Players Product Matrix
- CHAPTER NO. 5 : PESTEL & ADJACENT MARKET ANALYSIS
- CHAPTER NO. 6 : Polymyxin Resistance Testing Market – BY By Product ANALYSIS
- CHAPTER NO. 7 : Polymyxin Resistance Testing Market – BY By Testing Methods ANALYSIS
- CHAPTER NO. 8 : Polymyxin Resistance Testing Market – BY By End User ANALYSIS
- CHAPTER NO. 9 : Polymyxin Resistance Testing Market – BY By Region ANALYSIS
- CHAPTER NO. 10 : COMPANY PROFILES
- 10.1. Thermofisher Scientific
- Company Overview
- Product Portfolio
- Swot Analysis
- Business Strategy
- Financial Overview
- 10.2. Mast Group
- 10.3. Liofilchem
- 10.4. Rosco Diagnostica A/S
- 10.5. bioMérieux SA
- 10.6. Meridian
- 10.7. Beckman Coulter
- 10.8. Becton Dickenson & Company
- 10.9. Accelerate Diagnostics, Inc.
- 10.10. Bruker
- 10.11. EUCAST
- 10.12. Generon S.p.A.
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
